PT2857039T - Agente terapêutico ou profilático para demência - Google Patents

Agente terapêutico ou profilático para demência

Info

Publication number
PT2857039T
PT2857039T PT137972907T PT13797290T PT2857039T PT 2857039 T PT2857039 T PT 2857039T PT 137972907 T PT137972907 T PT 137972907T PT 13797290 T PT13797290 T PT 13797290T PT 2857039 T PT2857039 T PT 2857039T
Authority
PT
Portugal
Prior art keywords
agent
dementia
prophylactic
therapeutic agent
therapeutic
Prior art date
Application number
PT137972907T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Teijin Pharma Ltd
Univ Osaka City
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd, Univ Osaka City filed Critical Teijin Pharma Ltd
Publication of PT2857039T publication Critical patent/PT2857039T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711Alzheimer's disease; Amyloid plaque core protein
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT137972907T 2012-05-31 2013-05-30 Agente terapêutico ou profilático para demência PT2857039T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012124336 2012-05-31

Publications (1)

Publication Number Publication Date
PT2857039T true PT2857039T (pt) 2020-01-07

Family

ID=49673425

Family Applications (1)

Application Number Title Priority Date Filing Date
PT137972907T PT2857039T (pt) 2012-05-31 2013-05-30 Agente terapêutico ou profilático para demência

Country Status (30)

Country Link
US (3) US20150183854A1 (https=)
EP (2) EP2857039B1 (https=)
JP (3) JP5971659B2 (https=)
KR (2) KR102133610B1 (https=)
CN (1) CN104602708B (https=)
AR (1) AR091218A1 (https=)
AU (2) AU2013268364B2 (https=)
BR (1) BR112014029566A2 (https=)
CA (1) CA2875205C (https=)
CY (1) CY1122530T1 (https=)
DK (1) DK2857039T3 (https=)
ES (2) ES2973070T3 (https=)
HR (1) HRP20192267T1 (https=)
HU (1) HUE046919T2 (https=)
IL (1) IL235899B (https=)
LT (1) LT2857039T (https=)
ME (1) ME03587B (https=)
MX (1) MX361128B (https=)
MY (1) MY172458A (https=)
NZ (1) NZ630536A (https=)
PH (1) PH12014502669B1 (https=)
PL (1) PL2857039T3 (https=)
PT (1) PT2857039T (https=)
RS (1) RS59802B1 (https=)
RU (1) RU2657438C2 (https=)
SG (2) SG10201805410XA (https=)
SI (1) SI2857039T1 (https=)
TW (2) TWI700296B (https=)
WO (1) WO2013180238A1 (https=)
ZA (1) ZA201409186B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120244174A1 (en) 2011-01-31 2012-09-27 Intellect Neurosciences Inc. Treatment of tauopathies
JP6457263B2 (ja) * 2011-05-20 2019-01-23 オリゴメリックス インコーポレイテッド タウプロテアーゼ組成物および使用方法
PL2857039T3 (pl) * 2012-05-31 2020-05-18 Osaka City University Środek terapeutyczny lub środek profilaktyczny na otępienie
SG10201708959WA (en) 2012-07-03 2017-11-29 Univ Washington Antibodies to tau
TWI734975B (zh) * 2014-06-27 2021-08-01 美商C2N醫療診斷有限責任公司 人類化抗-tau抗體
US20190224339A1 (en) * 2016-04-29 2019-07-25 Voyager Therapeutics, Inc. Compositions for the treatment of disease
JP6785372B2 (ja) * 2016-09-30 2020-11-18 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 多重特異性分子の機能分析のためのsprに基づく二重結合アッセイ
SG11201907422RA (en) 2017-02-17 2019-09-27 Denali Therapeutics Inc Anti-tau antibodies and methods of use thereof
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
AR112600A1 (es) 2017-05-30 2019-11-20 Teijin Pharma Ltd Anticuerpo anti-receptor de igf-i
EP3691639B1 (en) 2017-10-02 2023-11-15 Merck Sharp & Dohme LLC Chromane monobactam compounds for the treatment of bacterial infections
AU2018352308B2 (en) 2017-10-16 2025-06-05 Eisai R&D Management Co., Ltd. Anti-tau antibodies and uses thereof
EP4471152A3 (en) 2018-04-06 2025-03-26 Teijin Pharma Limited Spns2 neutralizing antibody
EP3819378A4 (en) 2018-07-04 2022-09-14 Aichi Medical University OLIGONUCLEOTIDES FOR CONTROL OF TAU SPLICING AND THEIR USES
CN110028583B (zh) * 2019-05-07 2020-09-11 温州医科大学 抗Tau抗体及其在治疗阿尔茨海默病、创伤性脑损伤中的应用
GB2585252A (en) 2019-07-05 2021-01-06 Gen2 Neuroscience Ltd Tau epitope and binding molecules
JP7429404B2 (ja) * 2019-08-06 2024-02-08 慶應義塾 タウ関連疾患モデルの製造方法
US20220365102A1 (en) 2019-09-30 2022-11-17 Nipro Corporation Tau protein detection method using blood sample as test specimen
IL296611A (en) * 2020-03-19 2022-11-01 Vascular Biosciences Car peptide for improved coronavirus survival
CA3183835A1 (en) 2020-06-25 2021-12-30 Jeanne E. Baker High affinity antibodies targeting tau phosphorylated at serine 413
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
KR20250069606A (ko) 2022-09-15 2025-05-19 보이저 테라퓨틱스, 인크. 타우 결합 화합물
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS587390B2 (ja) 1975-03-11 1983-02-09 ツキシマキカイ カブシキガイシヤ ア−クヨウセツホウホウ
JP3587390B2 (ja) 1994-03-17 2004-11-10 タカラバイオ株式会社 リン酸化アミノ酸誘導体及びリン酸化ペプチド合成方法
US20020086009A1 (en) * 1996-03-13 2002-07-04 Koichi Ishiguro Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same
US20080199471A1 (en) * 2002-03-01 2008-08-21 Bernett Matthew J Optimized cd40 antibodies and methods of using the same
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US20070280935A1 (en) * 2006-04-07 2007-12-06 Bernd Bohrmann Antibody that recognizes phosphorylated peptides
EP2028932A4 (en) * 2006-06-16 2011-10-12 Vitruvean Llc TAU AND AMYLOID FOREIGNER FRAGMENT EXPRESSING TRANSGENIC FLY
UA107571C2 (xx) * 2009-04-03 2015-01-26 Фармацевтична композиція
CN106390107B (zh) 2009-06-10 2019-12-31 纽约大学 病理tau蛋白的免疫靶向
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
US20120244174A1 (en) * 2011-01-31 2012-09-27 Intellect Neurosciences Inc. Treatment of tauopathies
TR201102696U (tr) * 2011-05-27 2011-06-21 Turhal Sal�H Bağlantısız hareketli ürün reklam standı.
PL2857039T3 (pl) * 2012-05-31 2020-05-18 Osaka City University Środek terapeutyczny lub środek profilaktyczny na otępienie
JP2018139530A (ja) * 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤

Also Published As

Publication number Publication date
MY172458A (en) 2019-11-26
CY1122530T1 (el) 2021-01-27
PH12014502669B1 (en) 2020-02-19
HUE046919T2 (hu) 2020-04-28
PH12014502669A1 (en) 2015-02-02
JPWO2013180238A1 (ja) 2016-01-21
TW202041532A (zh) 2020-11-16
ZA201409186B (en) 2015-12-23
AU2018200413B2 (en) 2019-10-17
US20220340646A1 (en) 2022-10-27
AU2013268364B2 (en) 2018-02-08
KR102133610B1 (ko) 2020-07-14
AU2013268364A1 (en) 2014-12-18
MX2014014187A (es) 2015-06-04
RS59802B1 (sr) 2020-02-28
JP5971659B2 (ja) 2016-08-17
US20200148753A1 (en) 2020-05-14
EP2857039A1 (en) 2015-04-08
JP2018111716A (ja) 2018-07-19
RU2014153099A (ru) 2016-07-20
SG10201805410XA (en) 2018-08-30
HK1210031A1 (en) 2016-04-15
CN104602708A (zh) 2015-05-06
IL235899A0 (en) 2015-01-29
ME03587B (me) 2020-07-20
NZ630536A (en) 2017-03-31
CA2875205C (en) 2021-07-20
HRP20192267T1 (hr) 2020-03-20
CA2875205A1 (en) 2013-12-05
CN104602708B (zh) 2021-11-30
EP2857039B1 (en) 2019-11-20
JP6620829B2 (ja) 2019-12-18
ES2973070T3 (es) 2024-06-18
JP6406678B2 (ja) 2018-10-17
EP3662931A1 (en) 2020-06-10
US20150183854A1 (en) 2015-07-02
EP3662931B1 (en) 2023-12-06
TWI700296B (zh) 2020-08-01
EP2857039A4 (en) 2015-08-26
AR091218A1 (es) 2015-01-21
DK2857039T3 (da) 2019-12-16
MX361128B (es) 2018-11-28
IL235899B (en) 2019-03-31
AU2018200413A1 (en) 2018-02-08
PL2857039T3 (pl) 2020-05-18
SI2857039T1 (sl) 2020-03-31
KR20150027098A (ko) 2015-03-11
BR112014029566A2 (pt) 2017-07-25
LT2857039T (lt) 2020-03-10
TWI777183B (zh) 2022-09-11
KR102208283B1 (ko) 2021-01-26
JP2016147902A (ja) 2016-08-18
KR20200029619A (ko) 2020-03-18
SG11201407878VA (en) 2015-01-29
WO2013180238A1 (ja) 2013-12-05
RU2657438C2 (ru) 2018-06-13
TW201410705A (zh) 2014-03-16
ES2763361T3 (es) 2020-05-28

Similar Documents

Publication Publication Date Title
ZA201409186B (en) Therapeutic agent or prophylactic agent for dementia
PL3153144T3 (pl) Urządzenie izolacyjne
SG11201501173SA (en) PI3Kδ INHIBITOR
EP2913053A4 (en) THERAPEUTIC OR PROPHYLACTIC AGENT FOR TUMOR LYING SYNDROME
GB201217439D0 (en) Combination therapy
SG11201500074XA (en) Safety cabinet
PL2554541T3 (pl) Środek terapeutyczny lub środek profilaktyczny na fibromialgię
GB201207305D0 (en) Therapy
PL399419A1 (pl) Sposób wytwarzania 4-metoksydihydrochalkonu
PL399418A1 (pl) Sposób wytwarzania 4-metoksydihydrochalkonu
IL236450A (en) Process for making 5-fluoro-h1-pyrazoles
PL2677104T3 (pl) Szafka bezpieczeństwa
PT2861118T (pt) Conjunto sanitário
GB2502527B (en) Plumbing apparatus
GB2505665B (en) Residual range system
GB201220529D0 (en) No details available
GB201214234D0 (en) Prophylactic therapy
GB2499038B (en) Safety apparatus
GB201220253D0 (en) Plumbing apparatus
GB201211543D0 (en) Combination therapy
PL2861904T3 (pl) Ulepszone urządzenie instalacji wodociągowej
PL2677099T3 (pl) Szafka bezpieczeństwa
HUP1200675A2 (en) Process for the preparation of pyrimidinyl-piperazines
GB201213825D0 (en) Damper-device for bouncing-device
AU2012902592A0 (en) Danger Dummy Safety Dummy